Abstract
Purpose: :
Celecoxib (Cxb) has been shown to suppress lens epithelial cell (LEC) growth in vitro (Chandler, et al. Mol Vis 2007). Acrylic intraocular lenses (IOLs) have been shown to deliver Cxb after incubation in a sustained-release manner (Gilger, et al. ARVO Abstract 2008). The purpose of this study was to determine the effect of Cxb-incubated acrylic IOLs on LEC growth in a canine ex vivo model of posterior capsule opacity (PCO).
Methods: :
Canine acrylic IOLs (60V, AcriVet, Germany) were incubated for 24 hours in PBS / 25% DMSO solution only or a 300µM solution of Cxb (in PBS / 25% DMSO). In vitro release rates of Cxb in PBS from incubated IOLs were determined by HPLC for 28 days. Incubated and non-incubated IOLs were placed into lens capsules (LC) using the ex vivo PCO model that was created using cadaver eyes from young normal dogs. In addition, untreated LCs along with the IOL-treated LCs were maintained in DMEM media with antibiotics at 5% CO2 and 37°C for 28 days. Daily photographs were used to determine percent cellular ingrowth via image analysis software (ImageJ).
Results: :
Cxb was released from the Cxb-incubated IOLs at a rate of 0.6 to 1.0 µg/day for at least 7 days. LCs treated with non-incubated IOLs (n=3) had significantly less LEC growth than untreated LCs (n=6) on days 7 - 11 of culture. LCs treated with Cxb-incubated IOLs (n=6) had significantly less LEC growth than LCs without IOLs and those with non-incubated IOLs on days 2 - 28. LCs without treatment attained confluency by 14 days, LCs with untreated IOLs attained >90% confluency by 21 days, while Cxb-incubated IOLs did not reach >80% confluency by 28 days of culture.
Conclusions: :
LCs treated with acrylic IOLs incubated in 300µM Cxb had suppressed LEC ingrowth compared to untreated and IOL-only LCs. Further in vivo study is needed to determine if Cxb-treated IOLs can effectively prevent PCO.
Keywords: posterior capsular opacification (PCO) • intraocular lens • inflammation